Publications
- Nivolumab plus chemotherapy or ipilimumab in the first-line palliative therapy of esophageal, gastroesophageal junction, and gastric cancer2023 | Faculty of Medicine in Hradec Králové
- Prognostic value of blood cell count-derived ratios in BRAF-mutated metastatic melanoma2022 | Faculty of Medicine in Hradec Králové
- Adverse effects of combination immunotherapy in renal cancer, lung cancer, and melanoma +12022 | Faculty of Medicine in Hradec Králové
- Administration of Nivolumab in Metastatic Renal Cell Cancer Following Treatment With mTOR Inhibitors2021 | Faculty of Medicine in Hradec Králové, First Faculty of Medicine
- Adjuvant therapy of malignant melanoma: general and practical experience2021 | Faculty of Medicine in Hradec Králové
- Nivolumab induced encephalopathy in a man with metastatic renal celll cancer: a case report2018 | Faculty of Medicine in Hradec Králové
- Current possibilities of immunotherapy in the treatment of malignant melanoma2018 | Faculty of Medicine in Hradec Králové
- Immunoterapy related toxicities2017 | Faculty of Medicine in Hradec Králové
- MUC13-miRNA-4647 axis in colorectal cancer: Prospects to identifications of risk factors and clinical outcomes2023 | Faculty of Medicine in Hradec Králové, Faculty of Medicine in Pilsen, First Faculty of Medicine, Third Faculty of Medicine
- Differences in genome, transcriptome, miRNAome, and methylome in synchronous and metachronous liver metastasis of colorectal cancer2023 | Faculty of Medicine in Hradec Králové, Faculty of Medicine in Pilsen, First Faculty of Medicine, Third Faculty of Medicine
Loading network view...